| Name | Title | Contact Details |
|---|---|---|
Molly Henderson |
Chief Financial and Business Officer | Profile |
Tom Harris |
Head of Global Regulatory Affairs, Quality/R&D Systems, CMC and Biostatistics | Profile |
Karla Rowe |
Director, R&D Systems and Compliance | Profile |
Allen Secrest |
Vice President, R&D Operations | Profile |
Joseph Hand |
Chief Administrative Officer | Profile |
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance to our program teams to rapidly advance our candidates from research through all stages of development. We are headquartered in Boston, Massachusetts.
06795 Pfizer Inc. is an American multinational pharmaceutical corporation headquartered in New York City.
Our AI & AR powered technology reduces medical practice overhead, accelerates patient throughput, improves efficiency, and speeds up data collection.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.